Contact TrialAdvance | 312.339.2678 

 


Sponsor/Site Relationship Building
TrialAdvance Engagement-Training™
Investigator • CRC Workshops
Site Strategy • Communications
Site Performance Support
Study Site Action Plans
Diversity Training • Special Populations
Sponsor/Site Expectation Exchange
Patient Recruitment Strategy
Community Site Mapping
Patient Interviews • Focus Groups
Study Start-Up Planning
Rescue Study Tactics
Special Populations • Diversity
New Site/Investigator Development

Site Identification • Selection

Multicultural Site Recruitment

Site Operations Consulting
 
Tuesday, 28 February 2012 18:13

In Honor of Rare Disease Day

In honor of Rare Disease Day, February 29, 2012, I wanted to post some thoughts and increase awareness of this often overlooked issue.  To be considered "rare" there must be fewer than 200,000 patients affected by the disease in the United States, but in many cases, if numbers could be aggregated worldwide, it would paint a vastly different picture. As editor in chief of Contemporary Clinical Trials, I had the privilege of bringing attention to the efforts to create and maintain a registry for patients affected by this issue, spearheaded by the Office of Rare Diseases Research within the National Institutes of Health. I personally championed this topic and created a category for it in the journal. I believe this is an important initiative to bring help to these patients, so many of whom are children. To learn more about rare diseases please see http://www.rarediseaseday.org/.  To see the letter to the editor from the Office of Rare Diseases Research please see http://www.trialadvance.com/~trialadv/images/stories/InTheNews/patient%20registry%20contemporary%20clinical%20trials%202010.pdf
Tuesday, 10 January 2012 14:53

Kathleen Drennan's Recommended Articles

I highly recommend the article, Pharmas are lagging in online multicultural efforts. This is an important issue, to which I am very committed. This is so reminiscent of the industry recognizing women as key stakeholders in the drug development process. Reluctantly, it only started embracing women in clinical trials in the early 1990's, imagine. Women were not included in the early research because they were "too risky" and "expensive" to include in any significant numbers in clinical trials. Now all of that has changed and we can take lessons--we are still catching up, however now the science acknowledges that there are gender differences significant to research and drug development. In order for diverse populations to be truly included on the back end--branding/marketing, we must proactively include on the front end--early research--and it has to start with the science/protocols and integrated into every part of the strategic and tactical development process. For the industry, this is an exciting frontier that only the proactive are going reap the real benefits.

These comments were originally posted to the Minority Patient Recruitment discussion on LinkedIn (click here to follow).

Friday, 16 December 2011 16:46

Some Thoughts on Informed Consent

I recently ran across this article on Pharmalot, titled Informed Consent Forms Target 11th Grade Readers and as this topic is one about which I am extremely passionate, I wanted to comment further here.

Formal Informed Consent development for clinical trials is riddled with regulatory/legal requirements and interpretive language--and it is likely to stay that way.

I propose that this discussion is ultimately not just about the appropriate reading level to allow comprehension (historically set at an 8th grade level)-- but the race, culture, geography, experience, and numerous other factors that affect full comprehension at the individual level.

To obtain the desired results, those presenting informed consent need customizable resources that assist them in optimizing patient engagement, comprehension, and understanding. These tools can take various forms: DVDs, USBs, videos, power points, etc. that explain the meaning of the IC in the context of the individual patient. The materials should address issues related not only to general risk/benefit content, but other areas of specific concern that may vary by culture/ethnicity, language, age, geography, gender, and education.  A collateral document that accurately interprets content on all of these levels should accompany the formal IC. Without such guidance we are failing the very patient volunteers we are trying to engage and retain in important studies.

Admin © 2012 TrialAdvance, Inc.